139 related articles for article (PubMed ID: 37903288)
1. LONG-TERM USE OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Begaj T; Jeong D; Park JG; Runner MM; Capone A; Dass AB; Drenser KA; Faia LJ; Farley ND; Garretson BR; Hassan TS; Mahmoud TH; Margherio A; Raphaelian PV; Randhawa S; Ruby AJ; Sneed S; Rao P; Wolfe JD; Williams GA
Retina; 2024 Feb; 44(2):222-229. PubMed ID: 37903288
[TBL] [Abstract][Full Text] [Related]
2. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
Rahimy E; Rayess N; Ho AC; Regillo CD
Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
[TBL] [Abstract][Full Text] [Related]
3. TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.
Starr MR; Kung FF; Mejia CA; Bui YT; Bakri SJ
Retina; 2020 Sep; 40(9):1665-1672. PubMed ID: 31725524
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
5. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.
Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP
Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385
[TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor.
Prahs P; Brandl C; Helbig H; Volz C
Rom J Ophthalmol; 2023; 67(3):260-266. PubMed ID: 37876508
[No Abstract] [Full Text] [Related]
7. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
[TBL] [Abstract][Full Text] [Related]
8. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
[TBL] [Abstract][Full Text] [Related]
9. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT).
Meredith TA; McCannel CA; Barr C; Doft BH; Peskin E; Maguire MG; Martin DF; Prenner JL;
Ophthalmology; 2015 Apr; 122(4):817-21. PubMed ID: 25600198
[TBL] [Abstract][Full Text] [Related]
10. EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lee JH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS
Retina; 2019 Oct; 39(10):1953-1958. PubMed ID: 30161096
[TBL] [Abstract][Full Text] [Related]
11. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB
Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
[TBL] [Abstract][Full Text] [Related]
12. Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting.
Kataja M; Hujanen P; Huhtala H; Kaarniranta K; Tuulonen A; Uusitalo-Jarvinen H
Br J Ophthalmol; 2018 Jul; 102(7):959-965. PubMed ID: 29074495
[TBL] [Abstract][Full Text] [Related]
13. Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol.
Adrean SD; Chaili S; Ramkumar H; Pirouz A; Grant S
Ophthalmology; 2018 Jul; 125(7):1047-1053. PubMed ID: 29439828
[TBL] [Abstract][Full Text] [Related]
14. Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy.
Shienbaum G; Garcia Filho CA; Flynn HW; Nunes RP; Smiddy WE; Rosenfeld PJ
Am J Ophthalmol; 2013 Jun; 155(6):1009-13. PubMed ID: 23465269
[TBL] [Abstract][Full Text] [Related]
15. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
[TBL] [Abstract][Full Text] [Related]
16. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Follow-up of Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Kung FF; Starr MR; Bui YT; Mejia CA; Bakri SJ
Ophthalmol Retina; 2020 Nov; 4(11):1047-1053. PubMed ID: 32439455
[TBL] [Abstract][Full Text] [Related]
18. Insights From Survival Analyses During 12 Years of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
Fu DJ; Keenan TD; Faes L; Lim E; Wagner SK; Moraes G; Huemer J; Kern C; Patel PJ; Balaskas K; Sim DA; Bunce C; Stratton I; Keane PA
JAMA Ophthalmol; 2021 Jan; 139(1):57-67. PubMed ID: 33211064
[TBL] [Abstract][Full Text] [Related]
19. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
Bro T; Hägg S
Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
[TBL] [Abstract][Full Text] [Related]
20. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
